New Venturetec

Die fallen wie ein Stein, seit Wochen, sind die bald Pleite ?.

Was ist da los. Hab noch ein paar Scheinchen am "gammeln" im Depot :roll: :cry: ops: :roll: .

Press Release For further information:

November 5, 2007 Peter Friedli
Freigutstrasse 5
8002 Zürich
Tel: 044/283 29 00
Email: peter.friedli@friedlicorp.ch

New Venturetec with good results for the fiscal year 2006 / 2007 per September 30, 2007
Zürich, November 5, 2007. New Venturetec closed the fiscal year 06/07, ended September 30, 2007, with a profit of USD 11'066'671, compared to USD 10'088'153 in the fiscal year 05/06, an increase of 9.7%. The net asset value per share increased from USD 23.97 to USD 26.18 which equals 9.2% during the reporting period; in CHF respectively from 30.00 to 30.45 or 1.5%. The share price in the same
period decreased from CHF 26.20 to CHF 20.75, or 20.8%.

The net gain on investments of the reporting period is USD 17'814'627 compared to USD 17'730'768 in the same period 2006. The main reasons are Basilea Pharmaceutica's traded stock which increased by 34.4% and the increase on the Osiris Therapeutics holding by 27.5%.

The operational progress of the portfolio companies i s evident. As of September 30, 2007, New Venturetec had nine investments with six investments valued higher than the investment costs and three below investment costs. The net asset value is USD 130'892'004 compared to USD 94'823'590 paid-in and additional paid-in capital. This represents a total return on paid-in and additional paid-in capital of 38.0% as per September 31, 2007. No management fee earned in the reporting period was paid but rather accrued. The board remuneration for the reporting period was CHF 15'000.

Mr. Beat Wittmann announced to resign from the Board of Directors of New Venturetec at the Ordinary Shareholder Meeting 2007. The Board of Directors proposes to the General Assembly to elect Mr. Hans Lerch to the Board of Directors.

The annual report, including financial statements for the reporting period can be downloaded from www.newventuretec.com.

New Venturetec is a publicly traded Swiss investment company (SWX:NEV) which invests directly in venture capital companies predominantly in the USA.

The Ordinary Shareholder Meeting takes place November 27, 2007 at the Hotel Park Hyatt, Beethovenstrasse 21, 8002 Zürich from 11.45 until 13.30. The following companies will present:
Prolexys Pharmaceuticals and Osiris Therapeutics.